{
  "docId": "019de076-e634-7541-b7c2-0d86bd60f284",
  "docSlug": "a0435e4288abe83ccc65f275a885e9a2",
  "documentTitle": "Orthofix | Investor Presentation Deck | 22 slides",
  "authorId": "orthofix",
  "authorName": "Orthofix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 22,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a three-column layout to categorize the primary value drivers of the merger.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e634-7541-b7c2-0d86bd60f284/16",
  "deckHref": "/decks/019de076-e634-7541-b7c2-0d86bd60f284",
  "deckJsonHref": "/decks/019de076-e634-7541-b7c2-0d86bd60f284.json",
  "deckAnchorHref": "/decks/019de076-e634-7541-b7c2-0d86bd60f284#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*Revenue synergies of ~$25M expected by 2025. **Cost synergies of ~$50M expected by 2025 with incremental opportunity to reduce stock-based compensation expense. ***Based on due diligence, including revenue zip code analysis performed by 3rd party.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9afe938b-0b74-4580-a818-09ebb82ae887",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.22
      },
      "kind": "list",
      "text": "Complementary Portfolios: #1 Prescribed bone growth stimulator portfolio in the U.S., Broadest advanced DBM portfolio, market leading cellular allograft, and comprehensive line of synthetics, Next generation differentiated artificial cervical disc",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13da6f64-53e1-4a02-9311-cad7c0fab342",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "list",
      "text": "Meaningful Revenue & Cost Synergies: Est. Revenue Synergies: >$25M, Est. Cost Synergies: ~$50M, Revenue Risk to Manage: ~$20M, Working Capital & Capex Synergies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c902727b-e09f-4074-a0ac-4365bdd508ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.67,
        "y": 0.22
      },
      "kind": "list",
      "text": "Broader Commercial Reach: Accelerated adoption of differentiated technologies, Sustainable growth & value creation, Strengthened U.S. and international sales channels, Rapid product innovation driving market-share taking",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe433fb9-7876-4bd7-a8b3-f74583fd0aa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.32,
        "y": 0.05
      },
      "kind": "title",
      "text": "Merger Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd110b58-8bfa-4291-b399-a0932e80df17",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "03cb4b48-3e66-4a1e-9c8d-cb1682369683",
      "evidence": "list/bullet: Complementary Portfolios: #1 Prescribed bone growth stimulator portfolio in the U.S., Broadest advanced DBM portfolio, market leading cellular allograft, and comprehensive line of synthetics, Next generation",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 17,
      "from": 13,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "675716e0-a771-4f05-a254-617f397bc266",
      "evidence": "Slides 13-17 discuss key growth drivers and investment highlights",
      "position": 0,
      "objective": "Why now",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}